UK drug prescription levy rises 2.3%

20 March 2006

The UK's prescription charge is to increase from L6.50 ($11.38) to L6.65, an increase of about 2.3%, from April 1, but only for patients in England. The charge is a levy collected on each medication item, does not vary according to the quantity of product sold (two packs of the same drug are charged the same as a single pack) and means that the patient is not generally aware of the cost of a drug.

The UK government said that the increase was below the inflation rate of 2.4%. In a statement, Health Minister Jane Kennedy said: "this is a modest increase, which will help maintain the contribution that charges make towards the cost of the National Health Service," adding that exemptions mean that 87% of all drugs paid for by the taxpayer are issued free at the point of delivery.

In other parts of the UK, the prescription charge level and exemption criteria are decided upon by local assemblies (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight